|1.||Byrd, John C: 27 articles (05/2015 - 06/2005)|
|2.||Grever, Michael R: 23 articles (05/2015 - 06/2005)|
|3.||Grant, Steven: 23 articles (11/2014 - 02/2002)|
|4.||Johnson, Amy J: 15 articles (05/2015 - 01/2007)|
|5.||Phelps, Mitch A: 14 articles (04/2015 - 01/2007)|
|6.||Schwartz, Gary K: 14 articles (11/2012 - 04/2002)|
|7.||Lin, Thomas S: 12 articles (02/2014 - 04/2002)|
|8.||Karp, Judith E: 11 articles (12/2015 - 01/2003)|
|9.||Dent, Paul: 10 articles (08/2012 - 03/2002)|
|10.||Blum, Kristie A: 9 articles (04/2015 - 01/2007)|
01/01/2001 - "In addition, the present results suggest that flavopiridol may be more effective against types of cancer that are highly dependent on genes with unstable mRNAs."
03/25/2004 - "As an antitumor agent in mice, 21 administered at its maximum-tolerated dose exhibited a clearly superior efficacy profile when compared to flavopiridol in both an ip/ip P388 murine tumor model and in a s.c./i.p. "
07/15/2004 - "A fractional radiation dose of 6 Gy in combination with flavopiridol produced a 62.5% cure rate compared with 25% tumor cure for radiation alone. "
06/01/2004 - "Given the low toxicity profile of flavopiridol used as a single agent in patients, combination therapy now offers numerous opportunities in the near future to improve the efficacy of flavopiridol in the treatment of refractory cancers."
02/01/2004 - "We demonstrate efficacy of flavopiridol as a single modality treatment in delaying tumor growth in both animal models. "
|2.||B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
01/15/2007 - "Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia."
10/01/2013 - "Alvocidib has demonstrated efficacy in high-risk chronic lymphocytic leukemia (CLL) patients. "
03/01/2012 - "We retrospectively reviewed outcomes of refractory chronic lymphocytic leukemia patients in two age categories (≥70 and <70 years) treated with single-agent flavopiridol, a drug active in genomically high-risk patients, during two trials. "
12/10/2009 - "Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease."
03/19/2009 - "We previously reported interim results of a phase 1 trial in patients with chronic lymphocytic leukemia (CLL) whereby flavopiridol was administered intravenously as a 30-minute bolus followed by 4-hour infusion. "
07/01/2014 - "A screen of seven compounds with anti-CDK9 activity applied to a panel of leukemia cell lines identified flavopiridol and the experimental inhibitor PC585 as superior in efficacy with inhibitory concentrations in the submicromolar range. "
03/24/2011 - "Our phase 1 trial "hybrid FLAM" in 55 adults with relapsed/refractory acute leukemias began at a total flavopiridol dose of 50 mg/m(2) per day 3 times (20-mg/m(2) bolus, 30-mg/m(2) infusion). "
07/01/2010 - "Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias."
12/01/2005 - "These findings warrant continuing development of flavopiridol at 50 mg/m2/d x 3 days in combination with cytotoxic and biological agents for acute leukemias."
01/01/2005 - "Evidence of preliminary activity on the part of flavopiridol in certain chronic leukemias has pointed to that disease area as of potential interest, but likely by affecting transcriptional regulation through non-cell cycle-related CDKs. "
|4.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
11/01/2012 - "Both flavopiridol schedules produce comparably encouraging results in adults with poor-risk acute myelogenous leukemia. "
10/01/2011 - "Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia."
02/01/2007 - "Flavopiridol/vorinostat-mediated transcriptional repression of XIAP, Mcl-1-enhanced apoptosis, and loss of clonogenic potential also occurred in primary acute myelogenous leukemia (AML) blasts. "
06/01/2003 - "Both quercetin and flavopiridol inhibited the growth and viability of various acute myelogenous leukemia (AML) cell lines and AML blasts isolated afresh from patients with AML of various subtypes. "
11/01/2012 - "A phase II trial of flavopiridol followed by ara-C and mitoxantrone with flavopiridol given by 1-h bolus for adults with newly-diagnosed, poor-risk acute myelogenous leukemia yielded 67% complete remission with median disease-free survival of 13.6 months. "
|5.||Breast Neoplasms (Breast Cancer)
01/01/2000 - "Collectively, these molecular effects of flavopiridol, however, were found to be independent of c-erbB-2 overexpression, suggesting that flavopiridol may be effective in all breast cancer. "
03/01/2004 - "These data suggest that combinations of flavopiridol and signal transduction inhibitors warrant further studies as treatments for breast tumors, and that HER-2/neu expression may influence the choice of inhibitor to combine with flavopiridol."
06/01/2002 - "In this review, the rationale for using a CDK inhibitor as therapy for breast cancer is described and the preclinical studies performed with flavopiridol in breast cancer cell lines are highlighted. "
10/01/2000 - "Our previous study showed that flavopiridol induces cell growth inhibition and apoptosis in breast cancer cells. "
01/01/2015 - "Uptake of flavopiridol by OATPs also seems to be an important determinant in breast cancer cells. "
|10.||7-hydroxystaurosporine (UCN 01)
|1.||Heterologous Transplantation (Xenotransplantation)
|4.||Drug Therapy (Chemotherapy)